We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Rajesh Krishna, Senior Distinguished Scientist at Certara and a recognized leader in drug development. With 25+ years of experience, he’s shaped model-informed strategies for biologics, vaccines, and small molecules, and is consistently ranked among the top 2% of influential scientists.
Drug development is too slow and expensive. Certara helps companies design better trials, predict outcomes, and reduce risk using modeling, simulation, and AI. The goal is straightforward: make it faster and more efficient to bring safe and effective drugs to patients.
Check out the main topics of discussion for this episode of the Life Sciences Today podcast:
- Tell me about your journey.
- Tell me about Certara.
- Who are your customers?
- How do you create value?
- How do you capture value from customers?
- What are 3 things you want to do for your customers in the next 12-18 months?
Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast.
Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform:
Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube. Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn.
If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes.
Thanks so much for listening!
No comments:
Post a Comment